AZN’s PACIFIC Proves To Have Depth, ARDX Abuzz, No Flashy Data From ALLSTAR

http://ift.tt/2r9vWVw

Today’s Daily Dose brings you news about Ardelyx’ phase III study results of Tenapanor in irritable bowel syndrome with constipation; Capricor’s disappointing mid-stage trial data of CAP-1002; AstraZeneca’s encouraging results of Imfinzi in unresectable lung cancer and Ziopharm’s public offering.

May 14, 2017 at 10:30AM

http://ift.tt/2qeJYY0

from

http://ift.tt/2qeJYY0